Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine
- PMID: 6978196
- PMCID: PMC2396120
Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine
Abstract
Previous studies on the duration of antibody following vaccination with 17D yellow fever (17D YF) virus vaccine have indicated that immunity persists for at least 17 years and suggest that the vaccine may provide lifelong immunity. We studied sera obtained from 149 veterans of the Second World War, 30 - 35 years after military service during which YF vaccination was required for defined groups. A significantly high proportion of "vaccinated" subjects was found to be seropositive to 17D YF virus. The highest proportion of seropositive "vaccinated" veterans (97%) was among navy and air corps personnel, while only 60% of "vaccinated" army personnel and 19% of "unvaccinated" personnel were seropositive. This study suggests that (i) antibody to 17D YF virus, as measured by the plaque-reduction neutralization test (PRNT), persists for 30 years or more following administration of a potent vaccine; (ii) army personnel often had not received potent vaccine, even though their service history indicated that they should have been vaccinated; (iii) some personnel were vaccinated, although their service did not include vaccination-designated areas; and (iv) 88% of veterans with persistent PRNT antibody to 17D YF virus also had mouse-protective antibody against French neurotropic YF virus.
Similar articles
-
Growth of 17D yellow fever virus in a macrophage-like cell line, U937: role of Fc and viral receptors in antibody-mediated infection.J Immunol. 1981 Aug;127(2):659-65. J Immunol. 1981. PMID: 7252155
-
Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48.J Immunol. 1985 Oct;135(4):2805-9. J Immunol. 1985. PMID: 4031501
-
Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.Vaccine. 2007 Apr 20;25(16):3118-23. doi: 10.1016/j.vaccine.2007.01.053. Epub 2007 Jan 22. Vaccine. 2007. PMID: 17316925 Clinical Trial.
-
Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?Curr Opin Immunol. 2009 Jun;21(3):308-13. doi: 10.1016/j.coi.2009.05.018. Epub 2009 Jun 10. Curr Opin Immunol. 2009. PMID: 19520559 Review.
-
Stability of yellow fever vaccine.Dev Biol Stand. 1996;87:219-25. Dev Biol Stand. 1996. PMID: 8854020 Review.
Cited by
-
A safer cell-based yellow fever live attenuated vaccine protects mice against YFV infection.iScience. 2024 Sep 17;27(10):110972. doi: 10.1016/j.isci.2024.110972. eCollection 2024 Oct 18. iScience. 2024. PMID: 39398246 Free PMC article.
-
Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.Cell Rep Med. 2024 Jul 16;5(7):101655. doi: 10.1016/j.xcrm.2024.101655. Cell Rep Med. 2024. PMID: 39019010 Free PMC article.
-
African Green Monkeys Maintain Zika Virus Neutralizing Antibodies for at Least 1,427 Days Postinfection.Am J Trop Med Hyg. 2024 Apr 23;110(6):1178-1179. doi: 10.4269/ajtmh.23-0521. Print 2024 Jun 5. Am J Trop Med Hyg. 2024. PMID: 38653230
-
Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.J Virol. 2024 May 14;98(5):e0151623. doi: 10.1128/jvi.01516-23. Epub 2024 Apr 3. J Virol. 2024. PMID: 38567951 Free PMC article.
-
Prior flavivirus immunity skews the yellow fever vaccine response to cross-reactive antibodies with potential to enhance dengue virus infection.Nat Commun. 2024 Feb 24;15(1):1696. doi: 10.1038/s41467-024-45806-x. Nat Commun. 2024. PMID: 38402207 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
